Vectura Home » About Vectura » Track Record Track Record Our partners and licensees have succeeded in bringing DPI, pMDI and nebuliser medicines to market with the help of our specialist capabilities. SANDOZ Formulation + device + development 1 NOVARTIS Formulation 2 MUNDIPHARMA, KYORIN Formulation + device + development 3 BAYER Formulation + device + development 4 GSK Formulation 5 Our combination of formulation science, device technology and inhaled development expertise has contributed to the success of 13 inhaled medicines, launched by our partners and licensees. Since launch, they have generated $11 billion in sales and in 2020 these products were used by 10 million patients worldwide6 $11bn sales since launch 10m patients treated worldwide 1. Registered trade marks of Novartis AG 2. Registered trademarks of Novartis AG 3. flutiform® is a registered trade mark of Jagotec AG (in some territories, owned by Mundipharma AG). K-haler® is a registered trade mark of Mundipharma AG. 4. Breelib™ is a registered trade mark of Bayer Intellectual Property GmbH 5. Registered trade marks of Glaxo Group Ltd. Formulation technology licence, product not developed by Vectura. 6. Evaluate Pharma; internal estimates CAREERS ACCESSIBILITY TERMS & CONDITIONS COMMITMENT TO INCLUSIVITY MODERN SLAVERY ACT GENDER PAY GAP PRIVACY POLICY COOKIE STATEMENT SITE MAP BREELIB™ INSTRUCTIONS FOR USE ©2021 Vectura Group plc Designed and Developed by Naked Ideas